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Introduction
The use of mRNA-based vaccines in immunotherapy for can-
cer holds great promise. mRNA is an attractive candidate 
because it does not integrate into the genome of the host, it 
is safe, and easy to produce. The interest in using mRNA as 
a means to load dendritic cells (DCs) for the development of 
anticancer vaccines began to rise in the late 1990s, thanks to 
the pioneering work of E. Gilboa and colleagues at the Duke 
University.1–3 Nowadays, both ex vivo antigen loading4–6 and 
the direct administration of tumor-associated antigen mRNA 
to load DCs in vivo7–9 are under investigation. The success 
of both strategies depends on the uptake of the mRNA by 
the DCs in an efficient way and on the maturation status of 
the DCs when presenting antigenic peptides to immune cells. 
Several parameters of these mRNA-based cancer vaccines 
can be optimized, including the maturation stimuli, the choice 
of target antigen, and the presentation of antigenic peptide. 
We have shown that DCs matured by electroporation with Tri-
Mix mRNA (TriMix-DC) encoding CD40Ligand, CD70, and a 
constitutively active Toll-like receptor 4 (ca TLR4) are efficient 
T-cell stimulators.10,11 In 2009, a National Cancer Institute’s 
expert panel ranked and selected the most relevant tumor 
antigens for immunotherapeutic targeting.12 Antigen impor-
tance was determined using predefined and preweighted 
objective criteria, the most important being proof of thera-
peutic efficacy, immunogenicity and tumor specificity (repre-
senting together >60% of the relative weight). Although none 
of the evaluated antigens fulfilled all criteria of the ideal can-
cer antigen, the Wilms’ tumor 1 antigen (WT1) was ranked 
at position one in this list and can therefore be regarded as 
a highly suitable antigen. In the current study, we set out to 
optimize the presentation of WT1-derived antigenic peptides 
through the design of an optimized WT1 mRNA construct.
WT1 is a zinc-finger transcription factor that is encoded 
by the WT1 gene located on chromosome 11p13.13–15 It has 
a temporal and spatial expression pattern during the devel-
opment of the human urogenital system. After birth, nor-
mal tissue distribution of WT1 is restricted to the urogenital 
system, the central nervous system, and hematopoietic tis-
sues.14,16–18 By contrast, WT1 is aberrantly overexpressed in 
a wide range of malignancies and therefore considered as 
a nearly universal tumor-associated antigen. These charac-
teristics, as well as its established role in the malignant pro-
cess, render WT1 an attractive target for immunotherapeutic 
intervention.16,19,20
Received 9 July 2013; accepted 7 August 2013; advance online publication 19 November 2013. doi:10.1038/mtna.2013.54
2162-2531
e134
Molecular Therapy—Nucleic Acids
10.1038/mtna.2013.54
Original Article
19November2013
2
9July2013
7August2013
2013
© 2013 The American Society of Gene & Cell Therapy
Enhancing WT1 Protein Expression and Presentation
Benteyn et al.
Tumor antigen–encoding mRNA for dendritic cell (DC)-based vaccination has gained increasing popularity in recent years. 
Within this context, two main strategies have entered the clinical trial stage: the use of mRNA for ex vivo antigen loading 
of DCs and the direct application of mRNA as a source of antigen for DCs in vivo. DCs transfected with mRNA-encoding 
Wilms’ tumor 1 (WT1) protein have shown promising clinical results. Using a stepwise approach, we re-engineered a WT1 
cDNA-carrying transcription vector to improve the translational characteristics and immunogenicity of the transcribed mRNA. 
Different modifications were performed: (i) the WT1 sequence was flanked by the lysosomal targeting sequence of dendritic 
cell lysosomal-associated membrane protein to enhance cytoplasmic expression; (ii) the nuclear localization sequence (NLS) 
of WT1 was deleted to promote shuttling from the nucleus to the cytoplasm; (iii) the WT1 DNA sequence was optimized in silico 
to improve translational efficiency; and (iv) this WT1 sequence was cloned into an optimized RNA transcription vector. DCs 
electroporated with this optimized mRNA showed an improved ability to stimulate WT1-specific T-cell immunity. Furthermore, 
in a murine model, we were able to show the safety, immunogenicity, and therapeutic activity of this optimized mRNA. This work 
is relevant for the future development of improved mRNA-based vaccine strategies K.
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Several WT1 peptide vaccination trials have been performed 
in patients with hematological and solid malignancies,21 pro-
viding proof-of-concept that in vivo targeting of WT1 can elicit 
selective and WT1-specific antitumor immune responses.22,23 
Nevertheless, peptide vaccination has some limitations, in 
particular its human leukocyte antigen (HLA) restriction and 
the need for prior identification of immunogenic epitopes.
To circumvent these limitations, DCs electroporated with 
WT1-encoding mRNA have been used, allowing the intro-
duction of the full-length tumor antigen into the DC (multiepi-
tope vaccination), which is desirable to target a broad range 
of epitopes.24–27 Recently, Van Tendeloo et al. were able to 
demonstrate the immunogenicity and clinical efficacy of WT1 
mRNA-electroporated DC vaccinations in the postremission 
setting of acute myeloid leukemia, providing strong support 
for the further development and implementation of this immu-
notherapeutic approach.24,26 Besides the introduction of the 
entire tumor antigen into the DCs through mRNA electropor-
ation, an additional advantage of this strategy is that the anti-
gen of interest can be genetically modified.25 In this study, we 
aimed to design a novel WT1 mRNA construct with improved 
translational characteristics and enhanced immunogenic-
ity through a stepwise molecular engineering approach: (i) 
linking of the WT1 sequence with the lysosomal targeting 
signal of dendritic cell lysosomal-associated membrane pro-
tein (DC-LAMP);28–30 (ii) removal of the nuclear localization 
sequence (NLS) region from the WT1 sequence; (iii) in silico 
gene optimization for optimal codon usage and G/C content 
and for removal of factors known to affect translational effi-
cacy (e.g. splice sites)31,32; and (iv) subcloning of the entire 
sequence into a previously described RNA transcription 
 vector with enhanced translational properties.33
Results
Stepwise engineering of the WT1 mRNA constructs
Several molecular modifications were made to our original 
WT1 mRNA-encoding pGEM vector,34 further referred to as 
“wild-type WT1” mRNA. First, we removed the antigen’s nat-
ural 5′- and 3′-untranslated regions (UTRs), and we flanked 
the open reading frame of WT1 at its 5′-end by a signal pep-
tide (sig) to allow translocation to the endoplasmic reticulum 
(ER) and at its 3′-end by the transmembrane and cytoplasmic 
domains of DC-LAMP (CD208) to mediate transport of WT1 
to lysosomal compartments (pGEM/ΔUT/sig-WT1-DC-LAMP 
vector, coding for “WT1-DC-L” mRNA). To improve the cyto-
plasmic expression of WT1, a sequence containing the NLS 
of zinc-finger domain 135 was deleted resulting in the pGEM/
ΔUT/sig-WT1-NLS-DC-LAMP vector (encoding “WT1-sh-DC-
L” mRNA). Next, the insert of the latter vector was optimized 
in silico, resulting in the pGEM/ΔUT/sig-WT1-DC-LAMP OPT 
vector (encoding “WT1-sh-DC-L-OPT” mRNA). As a last modi-
fication step, we subcloned this optimized WT1 sequence into 
another vector, the pST1 vector. This RNA transcription vector 
can augment and prolong the antigen expression as shown 
Figure 1 Schematic of the different WT1-encoding vectors and quality control of the in vitro transcribed mRNA. (a) The T7 promoter, 
5′-UTR, 3′-UTR, human β-globin UTR, poly(A)-tail (A64 or A120), the NLS, sig, and the lysosomal targeting sequence (DC-LAMP) are shown. 
All pGEM constructs have an overhang of nucleotides derived from the vector backbone, which remains as 3′ attachment to the poly(A)-tail 
after linearization with SpeI. The pST1 vector has a free-ending poly(A)-tail after linearization with SapI. The original WT1 sequence is depicted 
in white and the optimized WT1 sequence in gray. (b) Electropherogram of the wild-type WT1 mRNA, representative of all mRNA samples, 
and (c) gel-like image of mRNA derived from the different WT1 constructs. NLS, nuclear localization sequence; sig, signal peptide; UTR, 
untranslated regions; WT1, Wilms’ tumor 1.
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by Holtkamp et al.33 The in vitro synthesized mRNA derived 
from the pST1 plasmid as template contains two consecutive 
3′-UTRs of the β-globin and a free-ending poly(A)-tail of 120 
adenosine residues. Figure 1a provides a schematic repre-
sentation of the different WT1-encoding vectors and their char-
acteristics. The quality, size, and concentration of the different 
in vitro transcribed mRNA constructs were analyzed with the 
Agilent 2100 Bioanalyzer (Figure 1b,c). All mRNA prepara-
tions derived from the different WT1-encoding constructs were 
of high quality, without impurities or mRNA degradation.
WT1 expression in K562 cells and human DCs
In a first set of experiments, K562 cells were electroporated 
with the different WT1-encoding mRNA constructs and ana-
lyzed for WT1 protein expression kinetics by flow cytometry. 
As shown in Figure 2a, all WT1 mRNA constructs yielded 
a maximal WT1 expression pattern 4-hour postelectropora-
tion with a rapid decline over time. WT1 expression was still 
detectable 24-hour postelectroporation but returned to base-
line levels 48-hour postelectroporation with the exception of 
the “WT1-sh-DC-L-OPT” mRNA transcribed from the pST1 
vector (Figure 2a). Similar results were obtained with DCs 
coelectroporated with TriMix mRNA combined with the WT1-
encoding mRNA molecules (data not shown), showing that 
the improvement of protein expression by these modifica-
tions is not cell type dependent and is also applicable to DCs. 
However, in comparison with K562 cells, the overall WT1 
expression was lower in DCs (Figure 2b).
Localization of the WT1 protein in human DCs
Immunocytochemistry for WT1 was performed to further 
investigate the impact of the above-mentioned mRNA modifi-
cations on the protein expression level and subcellular local-
ization 24 hours after coelectroporation of DCs with TriMix 
and WT1-encoding mRNA (Figure 2c). A control mRNA was 
included in the DC experiments as a control for nonspecific 
WT1 immunoreactivity. In contrast to TriMix-DCs electropor-
ated with control mRNA, low but detectable WT1 protein 
expression was observed in ~20% of the cells following elec-
troporation with wild-type WT1 mRNA. Localization of WT1 
immunoreactivity was almost exclusively restricted to the 
nucleus. Addition of the lysosomal targeting sequence of DC-
LAMP to the original WT1 mRNA construct (WT1-DC-L) in 
addition to the removal of the natural UTRs of the WT1 mRNA 
resulted in a substantial increase in protein expression, as 
demonstrated by the enhanced WT1 immunoreactivity in 
~50% of the electroporated DCs (% positive cells “WT1-DC-
L” versus “wild-type WT1”; P = 0.004). Further improvement 
in translational efficiency was observed after removal of the 
NLS (WT1-sh-DC-L), resulting in even higher WT1 immu-
nopositivity in 61.6 ± 4.1% of the cells (% positive cells “WT1-
sh-DC-L” versus “WT1-DC-L”; P = 0.02). Notably, deletion of 
the NLS clearly favored the cytoplasmic localization of WT1. 
The in silico optimization step (WT1-sh-DC-L-OPT) did not 
result in a further improvement of the translational character-
istics of WT1-sh-DC-L mRNA, as demonstrated by the identi-
cal WT1-immunostaining pattern and the comparable degree 
of WT1 protein expression (% positive cells “WT1-sh-DC-L-
OPT” versus “WT1-sh-DC-L”; P = 0.53). Immunocytochemi-
cal analysis of pST1-derived mRNA-electroporated DCs 
revealed a strong cytoplasmic expression of WT1 in nearly 
all cells (% positive cells “WT1-sh-DC-L-OPT” (pST1 vector) 
versus “WT1-sh-DC-L-OPT” (pGEM vector); P = 0.0002).
Antigen-specific T-cell stimulatory capacity of human 
DCs electroporated with the different WT1-encoding 
mRNA constructs
To compare their functional capacity, TriMix-DCs were coelec-
troporated with the different WT1-encoding mRNA constructs 
and cocultured at various time points  postelectroporation (4, 
24, and 48 hours) with a human HLA-A2-WT1126–134-restricted 
CD8+ T-cell clone. Antigen-specific release of interferon-γ (IFN-
γ) was measured after 20 hours of coculture. A summary of 
four independent antigen presentation assays is shown, where 
WT1-specific T-cells were stimulated with DCs 24 hours after 
electroporation (Figure 2d). A trend to an increased IFN-γ 
secretion was observed after every modification made to the 
WT1 sequence, except for the in silico optimization step. The 
antigen-presenting capacity of WT1 mRNA-electroporated DCs 
rapidly declined over time, and IFN-γ secretion was reduced by 
>50% in cocultures initiated 24-hour postelectroporation with 
DCs electroporated with pGEM-derived WT1 mRNA (data not 
shown). Nevertheless, at this time point, all optimized mRNAs 
resulted in higher IFN-γ secretion as compared with the maxi-
mum IFN-γ level observed with the wild-type mRNA (data not 
shown). We observed that subcloning the WT1 sequence into 
the pST1 vector significantly increased WT1 antigen presenta-
tion, as shown by the high IFN-γ release. Indeed, whereas the 
IFN-γ release of the T cells stimulated with DCs electroporated 
with mRNA derived from the pGEM vectors had disappeared 
48 hours after electroporation, DCs electroporated with the 
pST1-derived mRNA still exhibited stimulatory potential (data 
not shown). Compared with peptide-pulsed DCs, the stimula-
tory capacity of DCs electroporated with pST1-derived mRNA 
remained higher at 24 and 48 hours after electroporation, 
although they were comparable at 4-hour postelectroporation 
or postpeptide loading (Figure 2e).
In vivo CTL activation after immunization with WT1 mRNA
To further illustrate the superiority of the pST1-derived WT1-
sh-DC-L-OPT mRNA, we analyzed its functionality in an in 
vivo mouse model. This WT1-encoding mRNA was selected 
for further in vivo immunizations, given its demonstrated 
superiority over the other constructs during the in vitro exper-
iments. As a reference mRNA, the wild-type WT1 mRNA was 
used. Both constructs are of direct relevance from a transla-
tional clinical research perspective. The wild-type WT1 mRNA 
has already been used in clinical trials24,36, and the WT1-sh-
DC-L-OPT mRNA derived from the pST1 vector is currently 
being used in a clinical trial using mRNA-electroporated DCs 
for patients with solid malignancies (NCT01291420).
C57BL/6 mice were immunized via intranodal injection 
with TriMix mRNA together with the optimized WT1 mRNA 
or the wild-type WT1 mRNA, as described before.7 Five 
days after immunization, the in vivo WT1-specific cytotoxic 
T-lymphocyte (CTL) response was assessed in the spleen, 
the injected and noninjected lymph node, and the blood. We 
observed specific lysis of peptide-loaded target cells after 
immunization with both the optimized WT1 mRNA and wild-
type WT1 mRNA in each compartment. Importantly, the lysis 
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Figure 2 Expression and presentation of WT1 protein after electroporation with mRNA derived from the different WT1-encoding 
vectors. (a) Intracellular staining of WT1 in K562 cells. K562 cells were electroporated with the indicated WT1 mRNA constructs and analyzed 
for WT1 expression by intracellular staining 4-, 24-, and 48-hour postelectroporation (open histograms). As a control for nonspecific WT1 
immunoreactivity, parallel electroporations were performed with a control mRNA (pGEM/NEF-DC-LAMP), which yielded similar expression 
levels as the isotype controls (gray-filled histograms). This figure is representative of three independent experiments. (b) Comparison of WT1 
ΔMFI (MFI of positive population substracted by the basal WT1 epxression) values of the total K562 population and the total immature DC 
population after electroporation with WT1-sh-DC-L-OPT mRNA encoded by the pGEM vector. Data are presented as mean ± SEM of three 
independent experiments (**P = 0.0081). (c) Immunocytochemical detection of WT1 in TriMix-matured, WT1 mRNA-electroporated DCs. 
Immunocytochemistry for WT1 was performed on DCs fixated 24 hours after coelectroporation with WT1-encoding mRNA or control mRNA. 
Immunocytochemical staining patterns are shown from one representative experiment out of five (upper panel). Expression data were scored 
according to the staining intensity (middle panel) and according to the percentage of WT1-positive cells (lower panel; data are expressed as 
mean ± SEM of five independent experiments). (d) TriMix-DCs were coelectroporated with the indicated WT1 mRNA constructs or with the 
control mRNA. Twenty-four hours later, electroporated DCs were cocultured with the WT1-specific T-cell clone for 20 hours. IFN-γ release during 
this coculture was measured. Results are shown as mean ± SEM of three independent experiments (*P < 0.05). (e) Human HLA-A2+ TriMix-
DCs were loaded with the WT1 antigen either by electroporation with the pST1-derived WT1-sh-DC-L-OPT mRNA or by pulsing with the HLA-
A2-restricted WT1126–134 peptide. Negative controls included TriMix-DCs electroporated with the control mRNA specified above or pulsed with 
the HLA-A2-restricted Melan-A26-35 peptide. Four, 24, or 48 hours after antigen loading, cells were used to stimulate a human HLA-A2-restricted 
WT1126-134-specific CD8+ T-cell clone. IFN-γ release was measured by ELISA after a 20-hour coculture. DC, dendritic cell; ELISA, enzyme-linked 
immunosorbent assay; IFN-γ, interferon-γ; MFI, mean fluorescence intensity; SEM, standard error of the mean; WT1, Wilms’ tumor 1.
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observed after immunization with the optimized WT1-encod-
ing mRNA was significantly increased when compared with 
the lysis observed on immunization with the wild-type WT1 
mRNA (Figure 3a; P = 0.0002).
Therapeutic antitumor immunity by intranodal WT1 
mRNA immunization
C57BL/6 mice were inoculated subcutaneously with 
C1498-WT1 leukemia cells. On day 7, in the presence of a pal-
pable tumor, mice were immunized intranodally with control, 
wild-type WT1, or optimized WT1 mRNA in combination with 
TriMix mRNA. Mice from the control group showed rapid tumor 
growth (Figure 3b). Tumor volume of the optimized WT1 mRNA-
immunized mice was significantly better than the wild-type WT1 
(P < 0.01) and control group (P < 0.001). WT1 mRNA-immu-
nized mice inoculated with C1498 leukemia cells (not express-
ing WT1) could not reject the tumor (data not shown).
Toxicity of WT1 mRNA immunization
To investigate the autotoxicity against organs expressing WT1 
under physiological conditions, such as the kidney (Figure 4a), 
WT1 mRNA-immunized mice were screened for proteinuria 
twice a week for 24 day. In addition, histopathologic studies 
of the kidney, lung, and liver were performed 35 days after 
intranodal immunization. Neither the tissues examined nor the 
urinary analysis showed signs of autotoxicity (Figure 4b,c).
Discussion
Recently, WT1 has been selected by a National Cancer Insti-
tute expert panel as a very promising antigen candidate, 
which deserves the highest priority for implementation as a 
target antigen for cancer immunotherapy.12 WT1 functions 
as a transcription factor, explaining its predominant nuclear 
localization.37 This was confirmed by our results, demonstrat-
ing nuclear WT1 staining in DCs electroporated with mRNA 
encoding the full-length (wild-type) WT1 protein (Figure 2c). 
As could be expected from their nuclear localization and low 
WT1 expression level, these cells had an overall weak capac-
ity to stimulate WT1-specific T-cell immunity (Figure 2d). 
Although the wild-type WT1 mRNA has already been used in 
clinical studies with some positive results,24,36,38 we hypothe-
sized that the localization, expression level, and presentation 
of the WT1 antigen could be further enhanced by competent 
molecular design of the tumor antigen–encoding sequence.
In line with previous work from our group,28,29 we introduced 
a first modification of the wild-type WT1 mRNA by linking 
it to the lysosomal targeting sequence of DC-LAMP. In this 
study, we observed that the addition of the DC-LAMP signal 
redirects WT1 to the cytosol and dramatically improves the 
translational efficacy, resulting in an enhanced presenta-
tion of the antigen to CD8+ T-cells (Figure 2d and data not 
shown). This corroborates our previous work24,25 and of Sahin 
et al.39 showing that the coupling of antigens to the trafficking 
sequences of endosomal/lysosomal proteins augments the 
MHC I antigen presentation efficiency. Two possible reasons 
can account for this. First, peptides from mRNAs without lyso-
somal targeting sequence, such as DC-LAMP, are generated 
during the pioneer round of translation, the major source of 
antigenic peptides for the MHC class I pathway.40–42 Peptides 
from the WT1-DC-L mRNA, which includes the DC-LAMP 
sequence, are also generated via the pioneer round of trans-
lation for MHC I presentation, but in addition enter the lyso-
somal and endosomal MHC class II compartments. Via this 
route, cross-presentation of antigenic peptides by the MHC 
class I molecules can occur, and this in turn results in an over-
all superior CD8+ T-cell stimulation capacity. Another possible 
explanation has been described in a recent study by Kreiter 
et al.,39 showing that an increased MHC class I presentation is 
mainly mediated by the additional signal peptide at the N-ter-
minal. Their hypothesis is that antigens fused to a signal pep-
tide undergo translocation to the ER where misfolded proteins 
undergo rapid translocation to the cytosol. ER-associated 
degradation occurs by the proteasome in the vicinity of the 
ER. This results in rapid translocation of the peptides by TAP 
back into the ER, eventually leading to an increased MHC 
class I presentation. The first modification step also involved 
the deletion of the natural 5′- and 3′-UTRs of WT1. Although 
Figure 3 Functionality of the WT1 protein encoded by the 
optimized vector in an in vivo mouse model. (a) In vivo CTL 
assay after immunization with wild-type WT1 mRNA or mRNA 
encoded by the optimized vector. In vivo cytolysis of the target 
cells was assessed ex vivo by flow cytometry analysis of CFSElo 
or CFSEhi cells in the spleen, injected and noninjected lymph 
nodes, and the peripheral blood. Data shown are from the blood 
and are representative for the other compartments. This figure 
is representative of three independent experiments. Data are 
presented as the percentage of specific lysis. (b) C57BL/6 mice 
(n = 7) were inoculated with 5 × 105 C1498-WT1 cells s.c. 7 days 
later, and mice were immunized intranodally with control, wild-type 
WT1+TriMix, or optimized WT1+TriMix mRNA. Tumor volume was 
assessed (**P < 0.01; ***P < 0.001). WT1, Wilms’ tumor 1.
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we have not investigated the effect of the deletion of these 
UTRs separately, we argue that an isolated removal of the 
UTRs would not have a negative impact on the processing 
and the presentation of the antigen for several reasons. First, 
the pGEM vector without UTRs leads to a longer and stron-
ger protein expression after mRNA electroporation compared 
with a similar vector containing the 5′- and 3′-UTRs of the 
Xenopus laevis β-globin gene (unpublished data). Second, 
the expression of a transcription factor, such as WT1, is partly 
regulated by the stability of its mRNA. This can be controlled 
by its own UTRs as these sequences may therefore promote 
the degradation of the mRNA more rapidly.43 
As stated before, the WT1 protein is predominantly located 
in the nucleus. Transport of a transcription factor from the cyto-
plasm to the nucleus is usually driven by NLS present in the 
zinc-finger domains. We hypothesized that deleting the NLS of 
zinc-finger domain 1 would retain WT1 in the cytoplasm, result-
ing in an enhanced delivery of WT1 protein to the antigen-pro-
cessing compartments.16,35 Moreover, this would prevent the 
presence of two trafficking signals with opposite cellular desti-
nations, being the NLS for translocation to the nucleus and the 
DC-LAMP signal for rerouting to the cytosolic lysosomal com-
partments. Although, an NLS has been described in zinc-finger 
domain 3 of WT144 after the start of our study, we could show 
that the nuclear expression after electroporation with the WT1-
sh-DC-L mRNA was strongly diminished. Our results indicate 
that deletion of one WT1-derived NLS indeed led to a higher 
cytoplasmic expression level of WT1 and a subsequent gain 
in antigen processing and presentation (Figure 2c,d). It would 
be interesting to investigate the added influence of deleting the 
NLS in zinc-finger domain 3 in the future. A downside to this 
modification is that 57 amino acids (aa292-348) are deleted, 
resulting in a possible loss of WT1 epitopes. Several epitopes 
have been located in this region.20,45 Nevertheless, since only 
a relatively small portion of the total WT1 sequence is deleted 
(about 10%), we believe that the improvement in antigen 
expression and presentation observed after deletion of the NLS 
region outweighs the potential loss of immunogenic epitopes. 
In general, protein expression may be limited by the short 
half-life of the mRNA. Furthermore, translation may be ham-
pered by several characteristics of the mRNA (including rare 
codon usage, low G/C-content or presence of negatively cis-
acting motifs). In silico optimization can lead to an increase 
in protein expression, demonstrating the reliability and gen-
eral validity of this approach.31,32 Our observations also reveal 
some increased expression as seen with CD40Ligand and ca 
TLR4 (unpublished data). Nevertheless, for some genes such 
as CD70, sequence modification appears not to have a major 
impact on transgene expression (unpublished data). A similar 
observation was made in the present study for WT1. Indeed, 
we consistently found that the WT1-sh-DC-L-OPT mRNA 
construct was not superior to the WT1-sh-DC-L construct in 
terms of translational efficacy and T-cell stimulatory capacity, 
indicating that in silico sequence optimization is not useful for 
all genes. 
In a final step, we subcloned the optimized WT1-sh-DC-L-
OPT sequence into the pST1 vector containing two repeats 
of the 3′-UTR of human β-globin and a free-ending poly-A tail 
of 120 adenosine residues.33,43 These features are known to 
enhance the translation efficiency and stability of the mRNA. 
We were able to confirm that the use of pST1  vector–tran-
scribed mRNA results in a higher and longer-lasting WT1 
Figure 4 Autotoxicity-related side effects after WT1 immunization. (a) WT1 expression in the kidney under physiological conditions. 
(b) No proteinuria was observed in mice immunized with the optimized WT1 mRNA, indicating no damage to the kidney (n = 8 mice/group). 
(c)  No pathological changes, such as lymphocyte infiltration or tissue destruction and repair, were observed in the kidney, lung, or liver 
(negative control) of WT1 mRNA-immunized mice. WT1, Wilms’ tumor 1.
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antigen expression and presentation by DCs in vitro as com-
pared with the pGEM vector. In parallel, we observed that 
DCs electroporated with WT1 mRNA transcribed from the 
pST1 vector are superior to peptide-pulsed DCs for antigen-
specific T-cell stimulation. This can be ascribed to the pro-
longation of the half-life of pST1-derived mRNA, resulting in 
increased cumulative expression levels of the antigen that 
enables de novo generation and presentation of peptides over 
an extended period of time. Consequently, a high density of 
peptides will be presented for a longer time, which is essen-
tial for optimal T-cell stimulation. This is in clear contrast with 
peptide-pulsed DCs where peptides are loaded exogenously 
onto the MHC class I molecules, which is known to be a very 
dynamic process with a short half-life.46 
The superior T-cell stimulatory capacity of the optimized 
vector was confirmed in vivo. Intranodal injection of mRNA 
results in the uptake of RNA molecules by local DCs that 
are able to translate and present the antigen to the regional 
T-cells.7,47 Our in vivo results demonstrated that mice immu-
nized with the optimized WT1 mRNA together with TriMix 
mRNA had a higher WT1-specific lytic capacity than mice 
immunized with wild-type WT1 mRNA and TriMix. Moreover, 
we observed strong antitumor effects against WT1-overex-
pressing leukemia cells after immunization with the optimized 
WT1 mRNA, without overt signs of autoimmune toxicity. The 
lack of overt autoimmune toxicity indicates that the normal 
level of WT1 expression by the few WT1-expressing tissues 
may be inadequate for recognition by WT1-specific CTLs.
Altogether, our findings show that the modification of an 
antigen-encoding mRNA template harbors multiple options 
to optimize its antigen presentation efficacy. This study 
proves that molecular optimization of a strong immunogenic 
tumor-associated antigen, such as WT1, can result in a high 
surface density of MHC/peptide complexes for an extended 
period of time. As a result, sufficiently high stimulatory 
signals can lead to the activation of sufficient numbers of 
T-cells to elicit significant cytotoxic impact without inducing 
autotoxicity. In conclusion, these data have important impli-
cations for the future design of mRNA-based cancer vac-
cine strategies targeting WT1.
Materials and methods
Mice. Six-to 12-week-old, female C57BL/6 mice were pur-
chased from Harlan (Horst, The Netherlands). All the animals 
were maintained and treated according to the European 
guidelines for animal experimentation. All experiments were 
approved by the Ethical Committee for the use of laboratory 
animals of the Vrije Universiteit Brussel (CEP n°10-214-2).
Cells and media. Human DCs were generated as previously 
described.48 Cells were cultured in RPMI1640 medium (Lonza, 
Verviers, Belgium) supplemented with 5% fetal bovine serum 
(Harlan, Sera-Lab, West-Sussex, UK), 100 U/ml penicillin, and 
2 mmol/l L-glutamine (PS/L-GLU; Lonza). Antigen presentation 
assays were performed in stimulation medium consisting of 
Iscove’s modified Dulbecco’s medium (Gibco) supplemented 
with 1% heat-inactivated human AB serum (PAA Laboratories, 
Linz, Austria), PS/L-GLU, 1 mmol/l sodium pyruvate, non-
essential amino acids, 0.24 mmol/l L-asparagine, and 0.55 
mmol/l L-arginine (all from Lonza). C1498 is a WT1-negative 
leukemia cell line of C57BL/6 origin. C1498-WT1 was estab-
lished by transfection of murine WT1 cDNA into C1498 cells. 
C1498 and C1498-WT1 cells were cultured in Iscove's modi-
fied Dulbecco’s medium (Lonza) supplemented with 10% fetal 
bovine serum and PS/L-GLU. WT1 expression of C1498-WT1 
was maintained by culture in 0.5-mg/ml G418 (Alexis Bio-
chemicals, Belgium). Both cell lines are a kind gift from HE 
Kohrt (CCSR, Stanford University, Stanford, CA) and were 
tested by polymerase chain reaction for WT1 expression.
Genetic constructs. The cloning of the CD40Ligand-, CD70-, 
and ca TLR4-encoding plasmids has been described.7,10 In 
this study, the TriMix genes (human and mouse analogs) were 
optimized in silico to improve their performance (GENEART, 
Regensburg, Germany) and subcloned into the pST1 tran-
scription vector (kindly provided by U. Sahin, Johannes-Guten-
berg University, Mainz, Germany).49 pGEM/tNGFR encoding a 
truncated form of the nerve growth factor receptor (containing 
the extracellular and transmembrane fragments) used for in 
vivo experiments, and the pGEM/NEF-DC-LAMP constructs 
used for in vitro experiments were described previously.50,51
The pGEM/WT1 plasmid containing the full-length WT1 
cDNA flanked by its natural 5′- and 3′-UTRs and a poly(A)-
tail of 64 adenines has been described before.38 The pGEM/
ΔUT/sig-WT1-DC-LAMP plasmid was generated by cloning 
the WT1 cDNA in-frame as a BglII–BglII fragment between 
the sig and the lysosomal targeting sequence of DC-LAMP in 
the pGEM/ΔUT/sig-WT1-DC-LAMP vector without UTRs.28 To 
obtain the pGEM/ΔUT/sig-WT1-NLS-DC-LAMP vector, a 171 
bp (aa292-348) long sequence containing the NLS of zinc-
finger domain 1 was removed from the WT1 sequence.16,35 
In the next step, in silico multiparameter sequence optimiza-
tion of the sig-WT1-NLS-DC-LAMP sequence was performed 
using GENEART technology (sig-WT1-NLS-DC-LAMP-OPT). 
Finally, this optimized sequence was cloned into the pGEM 
and pST1 vectors. The latter contains a T7 promoter, 2-serial 
human 3′-β-globin UTRs, and a poly(A)-tail of 120 adenines.
In vitro transcription of mRNA. Before the in vitro mRNA syn-
thesis, the pGEM and pST1 plasmids were linearized with 
SpeI and SapI, respectively. The in vitro transcription and 
mRNA quality control were performed as described before.28 
The quality, size, and concentration of the different in vitro 
transcribed mRNA constructs were analyzed with the Agilent 
2100 Bioanalyzer (Diegem, Belgium).
Electroporation of DCs and K562. Four to five million cells 
were coelectroporated with WT1-encoding mRNA (20 µg) 
and TriMix mRNA (5µg of each component) to allow antigen 
loading and DC maturation, respectively. Electroporation was 
performed as described before.11 Immediately after electro-
poration, the cells were transferred to culture medium and 
incubated at 37 °C in a humidified 5% CO2 atmosphere.
Synthetic peptides and peptide pulsing. Synthetic pep-
tides corresponding to the HLA-A2-restricted epitopes of 
WT1 (aa126-134; RMFPNAPYL) and Melan-A (aa26-35; 
ELAGIGILTV) were purchased from Eurogentec (Seraing, 
 Belgium). HLA-A2+ DCs (5 × 105 cells/ml) were loaded with 
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 5 µg/ml peptide for 2 h. Subsequently, cells were washed and 
resuspended to a final density of 2 × 105 cells/ml.
Flow cytometry. To analyze intracellular WT1 expression, cells 
were fixed and permeabilized using the BD Cytofix/Cytoperm 
plus kit and stained intracellularly with an anti-WT1 mono-
clonal antibody (clone 6F-H2; Dako Cytomation, Carpinte-
ria, CA). An immunoglobulin G isotype-matched PE-labeled 
anti-mouse antibody was used as secondary Ab (Becton & 
Dickinson, Erembodegem, Belgium). Nonreactive isotype-
matched antibody (eBioscience, Vienna, Austria) was used 
as control. Data acquisition was performed on a FACSCanto 
flow cytometer (BD, Erembodegem, Belgium) and analyzed 
using FlowJo software.
Immunochemistry and histological examination. Immunocy-
tochemistry of electroporated DCs was performed on Sacco-
manno-fixed (Yvsolab, Turnhout, Belgium), paraffin-embedded 
cell-block sections (5 µm) using an anti-WT1 monoclonal anti-
body (clone 6F-H2; Dako, Heverlee, Belgium) and the EnVi-
sionTM FLEX detection system (Dako). Slides were examined 
quantitatively (percentage of WT1-positive cells) and qualita-
tively (signal intensity as compared with a WT1-positive con-
trol specimen) for expression of WT1 by light microscopy.
For histological examination, mice were killed by cervical 
dislocation at d35 postimmunization; kidney, lung, and liver 
were immediately prelevated for formalin fixation and paraffin 
embedding. Five-micrometer sections were cut and stained 
with periodic acid-Schiff and analyzed by light microscopy.
WT1-specific T-cell clone and in vitro antigen presentation 
assay. A human WT1-specific T-cell clone (B3) recognizing 
the HLA-A2-restricted WT1126–134 epitope was used. Clone B3 
was expanded in vitro using the rapid expansion protocol as 
previously described.52
To investigate the T-cell stimulatory capacity of human 
DCs, 2 × 104 electroporated and/or peptide-pulsed HLA-A2+ 
DCs were cocultured with 5 × 103 WT1-specific B3 T-cells. 
Cocultures were started 4, 24, or 48 hours after electropora-
tion. After 20 hours of coculture, supernatant was analyzed 
for the presence of IFN-γ by ELISA using commercially avail-
able antibodies (Thermo Scientific, Doornik, Belgium).
In vivo CTL induction. Mice were immunized intranodally 
with either control (truncated nerve growth factor receptor) 
mRNA, wild-type WT1 mRNA in combination with TriMix 
mRNA, or pST1-derived WT1-sh-DC-L-OPT mRNA in com-
bination with TriMix mRNA. To that end, 10 µg of each mRNA 
molecule was resuspended in a volume of 10 µl 0.8 Hartman 
solution (Baxter, Braine-l’Alleud, Belgium) and injected into 
the inguinal lymph node as described before.7
Five days later, spleen cells isolated from naive syngeneic 
mice were pulsed with an overlapping pool of WT1 peptides 
spanning the entire sequence (JPT, Innovative Peptide Solu-
tions, Berlin, Germany) at 1 µmol/l for 2 hours, after which 
they were labeled with 10 µmol/l carboxyfluoresceinsuccin-
imidyl ester (CFSE) (CFSEhi) (Life Technologies, Merelbeke, 
Belgium). These cells were mixed at a 1:1 ratio with unpulsed 
spleen cells labeled with 0.5 µmol/l CFSE (CFSElo). Ten mil-
lion- to twenty million-mixed CFSE-labeled cells were injected 
via the tail vein. Sixteen hours later, specific lysis of target 
cells was analyzed in spleen, peripheral blood, and (injected 
and noninjected) lymph nodes by flow cytometry. The per-
centage of killing was calculated as described in ref. 7.
Tumor rejection experiments. To assess the therapeutic effi-
cacy of intranodal WT1 immunizations, mice were inoculated 
with 5 × 105 C1498-WT1 cells on day 0 and immunized with a 
control (truncated nerve growth factor receptor) mRNA, the 
wild-type WT1, or the optimized WT1 mRNA in combination 
with TriMix mRNA 7 days later, as specified above. Mice were 
killed when the tumor reached a diameter of >2,500 mm.3
Urine collection. All animals were allowed ad libitum drinking 
water and free access to standard chow. During the course of 
the experiment, mice were housed in metabolic cages at differ-
ent time points for the collection of 24-hour urine samples. Pro-
teinuria was expressed as total urinary protein over creatinine.53
Statistical analysis. Data were analyzed with GraphPad 
Prism 5 software using a Student’s t-test for human experi-
ments or ANOVA with Bonferroni post hoc for in vivo experi-
ments. Findings were considered statistically significant 
when P  values were >0.05.
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